Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma
Background Immunotherapy emerged as a promising treatment option for multiple myeloma (MM) patients. However, therapeutic efficacy can be hampered by the presence of an immunosuppressive bone marrow microenvironment including myeloid cells. S100A9 was previously identified as a key regulator of myel...
Saved in:
Main Authors: | Marie Törngren, Rong Fan, Eline Menu, Helena Eriksson, Karin Vanderkerken, Andrew Chantry, Hatice Satilmis, Niels Vandewalle, Emma Verheye, Philip Vlummens, Anke Maes, Catharina Muylaert, Elke De Bruyne, Holly Evans, Nathan De Beule, Dirk Hose, Ken Maes, Karine Breckpot, Kim De Veirman |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-01-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/11/1/e005319.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Effects of Forodesine in Murine and Human Multiple Myeloma Cells
by: Liesbeth Bieghs, et al.
Published: (2010-01-01) -
William Faulkner : le père du texte
by: Astrid Maes
Published: (2020-02-01) -
Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma
by: Dirk Hose, et al.
Published: (2024-12-01) -
Correction: Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma
by: Dirk Hose, et al.
Published: (2025-01-01) -
Mechanisms of Bone Resorption in Periodontitis
by: Stefan A. Hienz, et al.
Published: (2015-01-01)